These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 19202428)

  • 1. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort.
    Fraunfelder FW; Winthrop K; Suhler E; Choi D; Fraunfelder FT
    Retina; 2009 Feb; 29(2):285-6; author reply 286-7. PubMed ID: 19202428
    [No Abstract]   [Full Text] [Related]  

  • 2. Postmarketing surveillance rates of uveitis and scleritis with bisphosphonates among a national veteran cohort.
    French DD; Margo CE
    Retina; 2008 Jun; 28(6):889-93. PubMed ID: 18536608
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bisphosphonates: uveitis and scleritis.
    Prescrire Int; 2013 May; 22(138):128. PubMed ID: 23819179
    [No Abstract]   [Full Text] [Related]  

  • 4. Inflammatory ocular adverse events with the use of oral bisphosphonates: a retrospective cohort study.
    Etminan M; Forooghian F; Maberley D
    CMAJ; 2012 May; 184(8):E431-4. PubMed ID: 22470169
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmarketing surveillance of corneal edema, Fuchs dystrophy, and amantadine use in the Veterans Health Administration.
    French DD; Margo CE
    Cornea; 2007 Oct; 26(9):1087-9. PubMed ID: 17893540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nodular scleritis following alendronate therapy.
    Tabbara KF
    Ocul Immunol Inflamm; 2008; 16(3):99-101. PubMed ID: 18569796
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Bisphosphonate-induced ocular and orbital inflammation].
    Jakobsen TS; Funding M
    Ugeskr Laeger; 2022 Jul; 184(28):. PubMed ID: 35959811
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Scleritis and Intraorbital Inflammation following Oral and Intravenous Bisphosphonates in a 66-Year-Old Man.
    Heck K; Malinina S; Palmowski A
    Klin Monbl Augenheilkd; 2024 Apr; 241(4):426-428. PubMed ID: 38653272
    [No Abstract]   [Full Text] [Related]  

  • 9. Bisphosphonate-associated scleritis: a case report and review.
    Leung S; Ashar BH; Miller RG
    South Med J; 2005 Jul; 98(7):733-5. PubMed ID: 16108245
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Uveitis due to bisphosphonates: A rare side effect?
    Martín Guillén S; Hurtado García R; Álvarez Cienfuegos A
    Reumatol Clin; 2016; 12(2):119. PubMed ID: 26091954
    [No Abstract]   [Full Text] [Related]  

  • 11. Zoledronate-induced anterior uveitis, scleritis and optic neuritis: a case report.
    Wolpert LE; Watts AR
    N Z Med J; 2021 Jun; 134(1537):91-94. PubMed ID: 34239165
    [No Abstract]   [Full Text] [Related]  

  • 12. Acute bilateral uveitis and right macular edema induced by a single infusion of zoledronic acid for the treatment of postmenopausal osteoporosis as a substitution for oral alendronate: a case report.
    Tian Y; Wang R; Liu L; Ma C; Lu Q; Yin F
    BMC Musculoskelet Disord; 2016 Feb; 17():72. PubMed ID: 26867651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-induced optic neuritis and uveitis secondary to bisphosphonates.
    Stack R; Tarr K
    N Z Med J; 2006 Mar; 119(1230):U1888. PubMed ID: 16532052
    [No Abstract]   [Full Text] [Related]  

  • 14. Corneal graft rejection precipitated by uveitis secondary to alendronate sodium therapy.
    Richards JC; Wiffen SJ
    Cornea; 2006 Oct; 25(9):1100-1. PubMed ID: 17133063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accuracy of the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) as a research tool for identification of patients with uveitis and scleritis.
    Uchiyama E; Faez S; Nasir H; Unizony SH; Plenge R; Papaliodis GN; Sobrin L
    Ophthalmic Epidemiol; 2015 Apr; 22(2):139-41. PubMed ID: 25777314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibandronate (Boniva): a new oral bisphosphonate.
    Med Lett Drugs Ther; 2005 Apr; 47(1207):35. PubMed ID: 15843783
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aminobisphosphonate-associated orbital and ocular inflammatory disease.
    Keren S; Leibovitch I; Ben Cnaan R; Neudorfer M; Fogel O; Greenman Y; Shulman S; Zur D; Habot-Wilner Z
    Acta Ophthalmol; 2019 Aug; 97(5):e792-e799. PubMed ID: 30816018
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reports of esophageal cancer with oral bisphosphonate use.
    Wysowski DK
    N Engl J Med; 2009 Jan; 360(1):89-90. PubMed ID: 19118315
    [No Abstract]   [Full Text] [Related]  

  • 19. Central serous chorioretinopathy and phosphodiesterase-5 inhibitors: a case-control postmarketing surveillance study.
    French DD; Margo CE
    Retina; 2010 Feb; 30(2):271-4. PubMed ID: 20010456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Risk of atypical femoral fractures and osteonecrosis of the jaw associated with alendronate use compared with other oral bisphosphonates.
    Kharazmi M; Hallberg P; Warfvinge G; Michaëlsson K
    Rheumatology (Oxford); 2014 Oct; 53(10):1911-3. PubMed ID: 25099769
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.